Starting in January 2015, ATC was rather proud to participate in m-RESIST project, a research & innovation project funded by the EU, aiming to empower patients with treatment-resistant schizophrenia in order to better self-manage their condition. The project’s primary goal was to examine how mHealth techniques could help in early intervention and treatment of schizophrenia, by promoting collaboration between patients, caregivers, and clinicians.
3 years later, the m-RESIST Final Review will be held on February 20, 2018, at the EC premises in Brussels, to validate project results and achievements. This project, of more than 3 million euro, developed an innovative disease management system focused on the needs of patients with Treatment-Resistant Schizophrenia, studying new therapeutic protocols and disease management methods using mobile technologies.
The project m-RESIST: “Mobile Therapeutic Attention for Patients with Treatment-Resistant” was funded by the European Commission and coordinated by TICSALUT Foundation in Spain with the participation of 11 partners from 7 countries (Spain, Finland, Greece, Italy, Belgium, Hungary, and Israel).
Through this project, the following results have been delivered:
- m-RESIST clinical Interventions for Treatment-Resistant Schizophrenia
- m-RESIST innovative clinical interventions for staff and professionals
- m-RESIST innovative mHealth system